GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

While generics may dominate due to cost advantages and meeting needs of a developing economy, there is a growing thrust ...

Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

(Reuters) -GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter, ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Augmentin continues to be the leading brand in the overall ... In the adult vaccines segment, GSK continues to build on the momentum of its Shingrix Herpes Zoster Vaccine (recombinant, adjuvanted), ...

GlaxoSmithKline said its key brands held ... and continued to stay in line with the respective category performance. Augmentin continues to be the leading brand in the overall Indian pharma ...

Revenue from operations rose to Rs 1,010 crore for the September quarter compared with Rs 957 crore in the year-ago period, ...

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.